Cullinan Metals Options Lithium Property, Thunder Bay, ON
October 31, 2022 09:30 ET
|
Cullinan Metals Corp.
VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cullinan Metals Corp. (CSE: CMT), (OTC: CMTNF), (FWB: 7KO) ("Cullinan" or the “Company) is pleased to announce that it has entered into...
Cullinan Metals Options a Graphite Property in Quebec
October 20, 2022 09:00 ET
|
Cullinan Metals Corp.
VANCOUVER, British Columbia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cullinan Metals Corp. (CSE: CMT) ("Cullinan" or the “Company”) is pleased to announce that it has entered into an option agreement (the...
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
January 10, 2022 06:30 ET
|
Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
January 05, 2022 09:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in...
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
January 04, 2022 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
December 16, 2021 06:30 ET
|
Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
December 13, 2021 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cemtrex Announces Settlement of Class Action Securities Lawsuit & Derivative Actions
October 17, 2018 08:45 ET
|
Cemtrex Inc.
Farmingdale, NY, Oct. 17, 2018 (GLOBE NEWSWIRE) -- – Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), a world leading technology and manufacturing company, announced today that the Company has agreed to...